Will Biosimilar Competition And Product-Hopping Save Regeneron’s Eylea Or Cancel Each Other Out?
Executive Summary
Biosimilar entrants look to help protect Regeneron’s currently marketed form of Eylea from the US’s new price negotiation law. But it likely hinges on how CMS views the company’s product-hopping plan.
You may also be interested in...
Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake
Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.
Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake
Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.
Medicare Price Negotiation And A New Twist On Product Hopping
Tactic generally used to foil generic or biosimilar competition may find a new use in combination with such competition to avoid price negotiation, legal experts observe.